Biomanufacturing Media
-
CHT Prepacked Process-Scale Columns
11/21/2022
Learn more about one company's prepacked column offerings and the standardized design and format available in a range of diameters and bed volumes.
-
Biopharma Resilience: CDMOs Secure Supply Chain Management
10/21/2022
Learn how SanKav Pharmaceuticals provides available medicine to market through available components, resources and raw materials that support on-time production lines and biomanufacturing processes.
-
RNA-LNP Manufacturing Technology Delivering Transformative Medicines
10/13/2022
NxGen™ microfluidic technology enables controlled and precise assembly of high-quality, uniform LNPs, ensuring reproducible scale-up of RNA-LNPs while maximizing drug loading and particle quality.
-
Oligonucleotide Opportunities In DMD With PepGen's James McArthur, Ph.D.
7/24/2022
Duchenne muscular dystrophy affects an estimated one in 3,500 male births worldwide. Approved treatments haven't demonstrated strong clinical outcomes, but James McArthur, Ph.D. and his team at PepGen are seeking to change that with a pipeline of disease-modifying peptide-conjugated oligo candidates derived from the company's EDO platform.
-
Keys To Successful mRNA Manufacturing
4/26/2022
How PCR-based technology can accelerate mRNA development and manufacturing and design principles/critical parameters to enable the rapid development of lipids for RNA formulation.
-
Supporting The Global Biopharma Industry With Single-Use Capacity Expansion
4/22/2022
Explore Cytiva’s brand new single-use production facility in Wales, UK. This facility forms part of Cytiva’s >$1.5 billion investment in increased capacity to support the growing needs of the biopharmaceutical industry and to increase regional supply.
-
The NanoAssemblr® Spark™ Robust Low Volume RNA-Lipid Nanoparticle Formulation
4/14/2022
Develop RNA-lipid nanoparticles (LNPs) in under 10 seconds for drug discovery and early preclinical development. The NanoAssemblr®️ Spark™ instrument enables rapid µL formulations to conserve limited and expensive ingredients with minimal waste.
-
Translation Of RNA Nanomedicines From Design To Clinical
4/14/2022
mRNA therapeutics are applicable to cancer immunotherapies, infectious diseases, and other indications that require protein replacement therapy or antibodies.
-
mRNA LNP Scale Up For GMP Vaccine Production
4/14/2022
Explore an overview of the development and scale-up activities needed to develop high quality lipid nanoparticles and progress this saRNA vaccine to the clinic.
-
Democratizing RNA Nanotherapeutics
4/14/2022
This webinar is presented by Dr. John P. Cooke, Chair of the Department of Cardiovascular Sciences at the Houston Methodist Research Institute, Director of the Center for Cardiovascular Regeneration, and Medical Director of the RNA Therapeutics Program in the Houston Methodist DeBakey Heart and Vascular Center.